Airway management

Ketamine, Etomidate, and Mortality in Emergency Department Intubations

JAMA Netw OpenPublished Cohort study

Authors' conclusion

In this cohort study of critically ill adults undergoing RSI, etomidate use was associated with higher in-hospital mortality at 7 and 28 days compared with ketamine.

Study context

Population
Critically ill adults undergoing rapid sequence intubation (RSI) in 18 Brazilian EDs (Brazilian Airway Registry Cooperation), March 2022–April 2024; preintubation cardiac arrest or immediate postintubation transfer excluded
Participants
1,810 adults
Exposure
Etomidate vs ketamine as sole induction agent for RSI
  • Etomidaten = 1,296
  • Ketaminen = 514reference
Outcome
28-day in-hospital mortality
Follow-up
28 days
Methodological detailstarget trial emulation, observational registry data, inverse probability of treatment weighting, multicentre (18 EDs)
  • Target trial emulation
  • Observational registry data
  • Inverse probability of treatment weighting
  • Multicentre (18 EDs)

Main finding

As reported in the abstract

28-day in-hospital mortality (weighted)
Each group vs ketamineRelative risk (95% CI)
Etomidate
1.14(1.03–1.27)
Each group vs ketamineRD (95% CI)
Etomidate
7.6%(2.0%–13.3%)

Observational data: associations, not effects.

Secondary outcomes

OutcomeEtomidateKetamineRR (95% CI)
7-day in-hospital mortality (weighted)35.2% (95% CI 32.0%–38.3%)30.1% (95% CI 23.5%–36.7%)1.19 (1.04–1.35)

First-attempt intubation success

No statistically significant difference

Safety

OutcomeEtomidateKetamineRR (95% CI)
New hemodynamic instability within 30 min after intubation · 30 minutesMore frequent with ketamine18.9% (95% CI 16.7%–21.0%)24.2% (95% CI 20.4%–28.0%)0.78 (0.64–0.95)

Severe hypoxemia and cardiac arrest within 30 min after intubation · 30 minutes

No statistically significant differences

Original publication

Ketamine, Etomidate, and Mortality in Emergency Department Intubations. JAMA Netw Open. Published 1 December 2025. doi:10.1001/jamanetworkopen.2025.48060

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.